Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Postoperative Recurrence of ROS1-Rearranged Lung Adenocarcinoma: A Case Series.

The Thoracic and cardiovascular surgeon - 1 Aug 2026

Miyata Ryo, Sumitomo Ryota, Nakanobo Ryo, Hamaji Masatsugu

Abstract excerpt

Abstract: Postoperative recurrence of c-ros oncogene 1 (ROS1)-rearranged non-small cell lung cancer is rarely reported, and the role of tyrosine kinase inhibitors (TKIs) remains unclear. We retrospectively reviewed four patients with completely resected ROS1-positive lung adenocarcinoma who developed recurrence, three receiving crizotinib. The median disease-free interval was 33.4 months, and the median overall...

Topics

Join the communities discussing this publication.

Adenocarcinoma of Lung
Crizotinib
Gene Rearrangement
Neoplasm Recurrence, Local
Pneumonectomy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Progression-Free Survival

Protein Kinase Inhibitors

Protein-Tyrosine Kinases

Source

Identifiers

PMID: 41386286
DOI: 10.1055/a-2768-2882

Genes

ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Postoperative Recurrence of ROS1-Rearranged Lung Adenocarcinoma: A Case Series.PMID 41386286Read ↗

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung CancerSemantic proximity Read ↗

Molecular Changes Associated with Acquired Resistance to Crizotinib in <i>ROS1</i> -Rearranged Non–Small Cell Lung CancerSemantic proximity Read ↗

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review.Semantic proximity Read ↗

Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer.Semantic proximity Read ↗

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted TherapiesSemantic proximity Read ↗

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.Semantic proximity Read ↗

Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Post-recurrence survival analysis of stage I non-small-cell lung cancer.Semantic proximity Read ↗

Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion.Semantic proximity Read ↗

Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients.Semantic proximity Read ↗

Is radical local therapy effective in postoperative recurrent EGFR-mutated non-small cell lung cancer?Semantic proximity Read ↗

<i><scp>ROS</scp>1</i> expression and translocations in non‐small‐cell lung cancer: clinicopathological analysis of 1478 casesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.